Progyny (PGNY) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 9% year-over-year to $304.1 million, surpassing $300 million for the first time, driven by client and covered lives growth in both fertility benefits and pharmacy solutions.

• Adjusted EBITDA increased 15% to $54.5 million, with margin expansion to 17.9%, marking a record quarterly result.

• Net income was $16.5 million ($0.17 per diluted share), up from $15 million ($0.15 per share) a year ago.

• Early selling season and 2025 client commitments are pacing ahead of last year, with high adoption of new products and strong demand across industries.

• Board authorized an additional $100 million share repurchase program, following $159.8–$200.1 million in buybacks through Q2.

Financial highlights

• Medical/fertility benefits revenue rose 12% to $194 million; pharmacy revenue increased 4% to $110.5 million.

• Gross profit grew 13% to $68.3 million, with gross margin up 80 basis points to 22.5%.

• SG&A costs improved to 10.3% of revenue, down from 10.8% last year.

• Operating cash flow for Q2 was $56.7 million, down from $76 million last year due to working capital and higher taxes.

• Ended Q2 with $262 million in cash, cash equivalents, and marketable securities, and no debt.

Outlook and guidance

• Q3 2024 revenue expected between $290 million and $303 million; full-year revenue now $1.165–$1.2 billion (7–10% growth at midpoint).

• Adjusted EBITDA for 2024 expected at $199–$209 million; net income $55.4–$62.4 million; Adjusted EPS $1.53–$1.61.

• Guidance revised down by 5% at midpoint due to lower-than-expected ART cycles per utilizer and a net reduction in covered lives.

• Guidance reflects lower revenue per utilizing member, though utilization rates remain strong.